Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX

Royce & Associates LP purchased a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 81,024 shares of the company’s stock, valued at approximately $955,000. Royce & Associates LP owned about 0.11% of Definium Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. BIT Capital GmbH bought a new stake in shares of Definium Therapeutics in the 3rd quarter valued at about $26,000. CWM LLC boosted its holdings in Definium Therapeutics by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after acquiring an additional 1,796 shares during the period. Fifth Third Bancorp grew its position in Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new position in Definium Therapeutics during the 3rd quarter worth approximately $46,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Trading Up 0.6%

Shares of DFTX opened at $17.66 on Friday. Definium Therapeutics, Inc. has a 1-year low of $4.70 and a 1-year high of $18.70. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 0.12. The firm’s 50-day moving average price is $16.08 and its 200-day moving average price is $13.07. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -8.29 and a beta of 2.56.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Royal Bank Of Canada boosted their price objective on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Wolfe Research started coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. HC Wainwright upped their price target on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Finally, JonesTrading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Definium Therapeutics has an average rating of “Buy” and an average price target of $35.70.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 25,791 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares in the company, valued at $10,236,972.55. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares in the company, valued at $5,589,078.75. The trade was a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 42,667 shares of company stock worth $561,071. Company insiders own 2.26% of the company’s stock.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $70 price target while materially raising long-range earnings forecasts (FY2028–FY2030: FY2028 to $0.72, FY2029 to $3.24, FY2030 to $5.32), supporting a bullish long-term thesis for DFTX. MarketBeat DFTX report
• Neutral Sentiment: Sector news: a Psychedelic roundup highlighted Helus Pharma’s Phase 2 HLP004 results — relevant for overall psychedelic/psychedelics-adjacent sentiment but not directly related to Definium’s programs. This can move group sentiment without directly changing DFTX fundamentals. Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
• Neutral Sentiment: Short-interest data reported a “large increase” but shows 0 shares and NaN change — likely a data/reporting anomaly. There’s no clear evidence of rising short pressure based on the provided figures, so this item shouldn’t be driving the move unless updated data appears.
• Negative Sentiment: HC Wainwright cut near-term estimates: quarterly EPS for Q1–Q4 2026 were lowered to ($0.46) from ($0.38) and FY2026/FY2027 forecasts were reduced (FY2026 now ($1.83) vs prior ($1.52); FY2027 now ($1.52) vs prior ($1.23)). Those nearer-term downgrades increase downside risk for the next 12–18 months and can weigh on sentiment despite the long-term upside case. MarketBeat DFTX report

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.